All-in-one dispensing system firefly

In this webinar by SPT Labtech and Alithea Genomics, we will introduce practical methods to eliminate bottlenecks in library preparation, from single-cell RNA-seq to bulk RNA-seq. - Streamlining rare cell workflows: By combining FLASH-seq and firefly, we can complete full-length scRNA-seq library preparation from low-input or FACS-sorted samples in one day. - Scaling up bulk RNA-seq: Achieve high-throughput screening compatible with 96/384 well plates using extraction-free, plate-based solutions like Total DRUG-seq. - Accelerating the process from sample to data: We will provide practical tips for reducing manual work and smoothly integrating automation. - Case studies: We will demonstrate the effectiveness through case studies and real data in various applications of RNA-seq.

SPT Labtech and CIT Genomics have partnered to provide an automated workflow for single-cell research. They have developed ready-to-use protocols compatible with 10x Genomics' Chromium technology on the firefly platform, achieving improved efficiency and reproducibility in experiments. This addresses the major challenge of scalability in single-cell transcriptomics, reducing barriers to research.

SPT Labtech and Agilent have announced an automated target enrichment protocol for firefly+, compatible with Agilent's SureSelect Max DNA library preparation kit, fully automating the library preparation process. This enhances reproducibility, reduces errors, and shortens time, supporting the efficiency of genomic analysis.

On July 9, 2025, SPT Labtech announced a strategic partnership with the startup Semarion, originating from the Cavendish Laboratory at the University of Cambridge. This partnership will integrate SPT Labtech's firefly automated pipetting system with Semarion's SemaCyte microcarrier technology, enabling a flexible and scalable automated workflow for cell assays. This innovative collaboration will make it possible to miniaturize and automate adhesion cell assays, which have traditionally been challenging, and is expected to improve efficiency and reproducibility. It will also be adaptable to image analysis-based high-content assays such as cell painting. Semarion's CEO, Jeroen Verheyen, stated, "This partnership will create a flexible and miniaturized workflow that will significantly accelerate the drug discovery process." The two companies plan to work on developing joint protocols, generating validation data, and optimizing workflow strategies to provide researchers with more adaptable cell-based drug discovery support tools.